VelosBio is a startup based in the United States, most recent round Acquired, 1 tracked investor.
VelosBio is a startup based in the United States. VelosBio has been acquired. Brouky records 1 investor associated with the company.
VelosBio is a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). Its lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.